Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension

Circulation

Volumn 101, Issue 20, 2000, Pages 2388-2392

  Wensel, Roland ^b   Opitz, Christian F ^b   Ewert, Ralf ^b   Bruch, Leonhard ^b   Kleber, Franz X ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

Exercise; Hypertension, pulmonary; Iloprost; Lung; Pulmonary heart disease

Indexed keywords

ILOPROST; OXYGEN; PROSTACYCLIN DERIVATIVE;

ADULT; ARTERIAL GAS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; GAS EXCHANGE; HUMAN; LUNG VASCULAR RESISTANCE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

EID: 0034704997     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.20.2388     Document Type: Article

References (29)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223.
2. Rich S, Levy PC. Characteristics of surviving and non-surviving patients with primary pulmonary hypertension. Am J Med. 1984;76:573-578.
3. Rubin LJ, for the ACCP Consensus Conference. ACCP Consensus Statement: primary pulmonary hypertension. Chest. 1993;104:236-250.
4. Palevsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80:1207-1221.
5. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. Circulation. 1989;80:1198-1206.
6. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
7. Packer M, Greenberg B, Massie B, et al. Deleterious effects of hydralazine in primary pulmonary hypertension. N Engl J Med. 1982;306: 1326-1331.
8. Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol. 1984;4:890-901.
9. Jones DK, Higgenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J. 1987;57:270-278.
10. Barst RJ, Rubin LJ, Long WA, et al, for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
11. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338: 273-277.
12. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
13. Bein T, Metz C, Keyl C, et al. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system. J Cardiovasc Pharmacol. 1996;27: 583-586.
14. Walmrath D, Schneider T, Pilch J, et al. Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS). Lancet. 1993;342:961-962.
15. Mikhail G, Gibbs MG, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary pulmonary hypertension. Eur Heart J. 1997;18:1499-1504.
16. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-824.
17. Weber KT, Kinasewitz GT, Janicki JS, et al. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation. 1982;65:1213-11223.
18. Beaver WL, Lamarra N, Wasserman K. Breath-by-breath measurement of true alveolar gas exchange. J Appl Physiol. 1981;51:1662-1675.
19. Wasserman K, Stringer WW, Casaburi R, et al. Determination of the anaerobic threshold by gas exchange: biochemical considerations, methodology and physiological effects. Z Kardiol. 1994;83(suppl III):1-12.
20. Kleber FX, Reindl I, Wernecke KD, et al. Dyspnoea in heart failure. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura; 1996:95-107.
21. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-3349.
22. Groves BM, Badesch DB, Donnellan K, et al. Acute hemodynamic effects of iloprost in primary (unexplained) pulmonary hypertension. Semin Respir Crit Care Med. 1994;15:230-237.
23. D'Alonzo GE, Gianotti LA, Pohil RL, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987;92:57-62.
24. Dantzker DR, Bower JS. Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. J Clin Invest. 1979;64:1050-1055.
25. Dantzker DR, D'Alonzo GE, Bower JS, et al. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. Am Rev Respir Dis. 1984;130:412-416.
26. Kleber FX, Vietzke G, Bauer U, et al. Impairment of ventilatory efficiency predicts prognosis in patients with chronic heart failure. Circulation. 1996;94(suppl I):I-374. Abstract.
27. Tuan Peng C, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997;29:1585-1590.
28. Reindl I, Kleber FX. Exertional hyperpnea in patients with chronic heart failure is a reversible cause of exercise intolerance. Basic Res Cardiol. 1996;91(suppl 1):37-43.
29. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112:485-491.